scholarly journals An Ontology to Model the International Rules for Multiple Primary Malignant Tumours in Cancer Registration

2021 ◽  
Vol 11 (16) ◽  
pp. 7233
Author(s):  
Nicholas Charles Nicholson ◽  
Francesco Giusti ◽  
Manola Bettio ◽  
Raquel Negrao Carvalho ◽  
Nadya Dimitrova ◽  
...  
Keyword(s):  
Description Logic ◽  
Large Data ◽  
Population Based ◽  
Cancer Registration ◽  
Multiple Primary Cancers ◽  
Malignant Tumours ◽  
Data Set ◽  
Cancer Registry Data ◽  
Ontology Language ◽  
Multiple Primary

Population-based cancer registry data provide a key epidemiological resource for monitoring cancer in defined populations. Validation of the data variables contributing to a common data set is necessary to remove statistical bias; the process is currently performed centrally. An ontology-based approach promises advantages in devolving the validation process to the registry level but the checks regarding multiple primary tumours have presented a hurdle. This work presents a solution by modelling the international rules for multiple primary cancers in description logic. Topography groupings described in the rules had to be further categorised in order to simplify the axioms. Description logic expressivity was constrained as far as possible for reasons of automatic reasoning performance. The axioms were consistently able to trap all the different types of scenarios signalling violation of the rules. Batch processing of many records were performed using the Web Ontology Language application programme interface. Performance issues were circumvented for large data sets using the software interface to perform the reasoning operations on the basis of the axioms encoded in the ontology. These results remove one remaining hurdle in developing a purely ontology-based solution for performing the European harmonised data-quality checks, with a number of inherent advantages including the formalisation and integration of the validation rules within the domain data model itself.

Synchronous and Metachronous Diagnosis of Multiple Primary Cancers

1998 ◽  
Vol 84 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Emanuele Crocetti ◽  
Stefania Arniani ◽  
Eva Buiatti
Keyword(s):  
Renal Cell ◽  
Case Series ◽  
Population Based ◽  
Multiple Primary Cancers ◽  
Renal Cell Carcinomas ◽  
Time Period ◽  
Skin Cancers ◽  
Multiple Primary ◽  
Synchronous Cancers ◽  
Slow Growing

Aims In the time period near to the diagnosis of a new cancer, other tumors (synchronous cancers), especially slow-growing tumors, may be detected because several diagnostic examinations are performed. The frequency of synchronous in comparison with metachronous carcinomas has been evaluated in a population-based series of multiple primary cancers. Methods The case series of multiple primary cancers of the Tuscany Tumor Registry, incident during the period 1985-1991 was analyzed. For each site of a second independent tumor, the proportions of synchronous (diagnosed within 2 months of the first primary) and metachronous cancers were compared with the mean distribution (all sites except the specific one). Results During 1985-1991, 1095 patients had two independent tumors diagnosed; 216 were synchronous. The proportion of synchronous compared to metachronous cancers was significantly higher for bladder, prostate and renal cell carcinomas; it was significantly lower for lung cancer. When cancers following skin epitheliomas were evaluated, only the proportion of synchronous skin cancers was significantly increased. Conclusions Silent slow-growing tumors are suspected to be more frequent in patients with prostate, bladder or renal cell carcinomas. In fact, they were most frequently diagnosed during ascertainment for another cancer. When few examinations were performed, as after the diagnosis of a skin epithelioma, no difference between metachronous and synchronous cancers was evident, except for skin.

Incidence Patterns and Survival of Gynecological Sarcoma in Germany: Analysis of Population-Based Cancer Registry Data on 1066 Women

2018 ◽  
Vol 28 (1) ◽  
pp. 134-138 ◽  
Author(s):  
Klaus Pietzner ◽  
Nina Buttmann-Schweiger ◽  
Jalid Sehouli ◽  
Klaus Kraywinkel
Keyword(s):  
Cancer Registry ◽  
Survival Rates ◽  
Female Genital Tract ◽  
Relative Survival ◽  
Endometrial Stromal Sarcoma ◽  
Population Based ◽  
Registry Data ◽  
Uterine Leiomyosarcoma ◽  
Data Set ◽  
Cancer Registry Data

ObjectiveSarcomas of the female genital tract are rare tumors. They are described to be associated with a poor prognosis when compared with gynecogical carcinoma. The aim of this study was to report incidence patterns and survival rates for gynecological sarcoma (GS) in Germany.Methods/MaterialsClinical data and survival rates for patients with GS diagnosed in Germany between 2009 and 2013 were extracted from the German national center for population-based cancer registry data. Incidence patterns and 5-year relative survival rates were calculated.ResultsA total of 1066 GSs were included in our analysis during a 5-year time span. The uterus was the most common site, with 87.9% of all cases. The annual age-standardized incidence rate (old European standard) was 8.7 per 1 million women for all GSs. The median age at diagnosis was 59 years. The prognosis ranged according to site, stage, and subtype, for example, from a 5-year relative survival of 53.0% (uterine leiomyosarcoma) if confined to the pelvis, to a very good 5-year relative survival of 97.2% (endometrial stromal sarcoma).ConclusionsDespite the rareness of GS, the size of the data set allows for a differentiation of subtypes according to morphology and site of origin. Clinically relevant differences in incidence and prognosis between subgroups were observed.

Racial and age differences in multiple primary cancers after breast cancer: A population-based analysis

1989 ◽  
Vol 14 (2) ◽  
pp. 245-254 ◽  
Author(s):  
Ann Grossbart Schwartz ◽  
Nawal E. Ragheb ◽  
G. Marie Swanson ◽  
William A. Satariano
Keyword(s):  
Breast Cancer ◽  
Age Differences ◽  
Population Based ◽  
Multiple Primary Cancers ◽  
Multiple Primary

scholarly journals Dotting the “i” of Interoperability in FAIR Cancer-Registry Data Sets

2021 ◽  
Author(s):  
Nicholas Nicholson ◽  
Francesco Giusti ◽  
Luciana Neamtiu ◽  
Giorgia Randi ◽  
Tadeusz Dyba ◽  
...  
Keyword(s):  
Cancer Registry ◽  
Description Logic ◽  
Description Logics ◽  
Population Based ◽  
Domain Model ◽  
Registry Data ◽  
Data Sets ◽  
Cancer Registry Data ◽  
Fair Principles ◽  
Quality Dimensions

To conform to FAIR principles, data should be findable, accessible, interoperable, and reusable. Whereas tools exist for making data findable and accessible, interoperability is not straightforward and can limit data reusability. Most interoperability-based solutions address semantic description and metadata linkage, but these alone are not sufficient for the requirements of inter-comparison of population-based cancer data, where strict adherence to data-rules is of paramount importance. Ontologies, and more importantly their formalism in description logics, can play a key role in the automation of data-harmonization processes predominantly via the formalization of the data validation rules within the data-domain model. This in turn leads to a potential quality metric allowing users or agents to determine the limitations in the interpretation and comparability of the data. An approach is described for cancer-registry data with practical examples of how the validation rules can be modeled with description logic. Conformance of data to the rules can be quantified to provide metrics for several quality dimensions. Integrating these with metrics derived for other quality dimensions using tools such as data-shape languages and data-completion tests builds up a data-quality context to serve as an additional component in the FAIR digital object to support interoperability in the wider sense.

scholarly journals Data from Population-based Cancer Registration for Secondary Data Analysis: Methodological Challenges and Perspectives

2019 ◽  
Vol 82 (S 01) ◽  
pp. S62-S71 ◽  
Author(s):  
Volker Arndt ◽  
Bernd Holleczek ◽  
Hiltraud Kajüter ◽  
Sabine Luttmann ◽  
Alice Nennecke ◽  
...  
Keyword(s):  
Data Analysis ◽  
Cancer Registry ◽  
Secondary Data ◽  
Cancer Registries ◽  
Population Based ◽  
Secondary Data Analysis ◽  
Data Availability ◽  
Registry Data ◽  
Cancer Registration ◽  
Cancer Registry Data

AbstractPopulation-based cancer registries have a long-standing role in cancer monitoring. Scientific use of cancer registry data is one important purpose of cancer registration, but use of cancer registry data is not restricted to cancer registries. Cancer registration in Germany is currently heading towards population-based collection of detailed clinical data. This development together with additional options for record linkage and long-term follow-up will offer new opportunities for health services and outcome research. Both regional population-based registries and the German Centre for Cancer Registry Data (ZfKD) at the Robert Koch-Institute as well as international cancer registries and consortia or organizations may provide external researchers access to individual or aggregate level data for secondary data analysis. In this review, we elaborate on the access to cancer registry data for research purposes, availability of specific data items, and options for data linkage with external data sources. We also discuss as well as on limitations in data availability and quality, and describe typical biases in design and analysis.

Improved Survival Rates Among Acute Myeloid Leukemia (AML) Patients 65 to 74 Years: Population-Based Estimates Over Three Decades,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3591-3591 ◽  
Author(s):  
Mya S Thein ◽  
Ahmedin Jemal ◽  
Maria R. Baer ◽  
William B Ershler ◽  
Jerome W Yates
Keyword(s):  
Overall Survival ◽  
Conflicts Of Interest ◽  
Oldest Old ◽  
Survival Rates ◽  
Large Data ◽  
Population Based ◽  
Age Group ◽  
Acute Leukemias ◽  
Data Set ◽  
Improvement In Survival

Abstract Abstract 3591 Background: AML is the common acute leukemia in adults, accounting for approximately 90% of all acute leukemias in those over the age of 18 years. Overall survival remains poor, with <50% 5-year survival in patients under 45 years and <5% in those over 65 years. We examined whether there has been improvement in survival over three successive decades for subsets of geriatric AML patients. Methods: Examining data from the Surveillance, Epidemiology and End Results (SEER) database, we determined relative overall survival (+/− standard error) of patients with AML 65–74, 75–84 and 85+ years of age between 1977–86, 1987–96 and 1997–2006. Results: Survival for both males and females at 12, 24 and 36 months post-diagnosis is shown below. Between 1977–1986 and 1987–1996, 12-month, 24-month and 36-month survival rates increased from 20% to 25%, 10% to 13.1%, and 5.5 to 8.4%, respectively, in the 65–74 year age group. Between 1987–1996 and 1997–2006, 12-month, 24-month and 36-month survival rates increased from 25% to 30%, 13% to 17% and 8.4% to 11.7%, respectively, in the same age group. Survival rates increased over each decade in patients younger than 75 years of age, but did not improve significantly in patients 75 years and older. Female patients exhibited better survival up to 24 months than males in all age categories. The oldest-old (85+ years) had the lowest survival rates, with no apparent improvement over the past 3 decades for either gender. Conclusions: Analysis of a large data-set demonstrated that overall survival remains unsatisfactory over a 3-decade period among older patients, but has in fact improved in the young-old (65–74 year age group). Neither standard nor newly developed chemotherapy regimens have favorably impacted survival for the oldest-old AML patients, and intervention in this age group is best undertaken on a clinical trial. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document